Cochrane Abstracts
Terlipressin versus other vasoactive drugs for hepatorenal syndrome
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Terlipressin Versus Other Vasoactive Drugs for Hepatorenal Syndrome." Cochrane Abstracts, John Wiley & Sons, Inc, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/438822/all/Terlipressin_versus_other_vasoactive_drugs_for_hepatorenal_syndrome.
Terlipressin versus other vasoactive drugs for hepatorenal syndrome. Cochrane Abstracts. John Wiley & Sons, Inc; 2025. https://evidence.unboundmedicine.com/evidence/view/Cochrane/438822/all/Terlipressin_versus_other_vasoactive_drugs_for_hepatorenal_syndrome. Accessed March 21, 2025.
Terlipressin versus other vasoactive drugs for hepatorenal syndrome. (2025). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/438822/all/Terlipressin_versus_other_vasoactive_drugs_for_hepatorenal_syndrome
Terlipressin Versus Other Vasoactive Drugs for Hepatorenal Syndrome [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2025. [cited 2025 March 21]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/438822/all/Terlipressin_versus_other_vasoactive_drugs_for_hepatorenal_syndrome.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Terlipressin versus other vasoactive drugs for hepatorenal syndrome
ID - 438822
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/438822/all/Terlipressin_versus_other_vasoactive_drugs_for_hepatorenal_syndrome
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
